TheraSphere With Durvalumab and Tremelimumab for HCC
Clinical trial NCT05063565 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05063565
- Sponsor
- Boston Scientific Corporation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-03
- Primary completion
- 2027-06-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.